The demineralized bone matrix consists of natural bone minerals that are allografts derived from human bone tissue. These graft materials provide osteoconductive scaffolding for new bone growth and serve as a substitute for autogenous bone grafts. Demineralized bone matrix is used for bone regeneration in orthopedic, dental and maxillofacial surgeries. It acts as an osteoconductive scaffold that promotes bone formation through natural mineralized tissue derived from human.
The Global Demineralized Bone Matrix Market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.15 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Key Takeaways
Key players operating in the Demineralized Bone Matrix market are Medtronic plc, Johnson Johnson (DePuy Synthes), Zimmer Biomet, Stryker, SeaSpine, Xtant Medical, RTI Surgical, HansBioMed, Arthrex GmbH, Exactech, Inc., AlloSource, Halma (Novabone), Institut Straumann AG, Orthofix Holdings, Inc., Straumann, Synthes, Integra LifeSciences, Musculoskeletal Transplant Foundation (MTF), Bacterin International, and Osiris Therapeutics.
The geriatric population and rising number of sports injuries and accidents are increasing the demand for various orthopedic surgeries. This in turn is driving the Demineralized Bone Matrix Market Demand in bone regeneration procedures.
Geographically, North America dominated the global demineralized bone matrix market in 2020. However, Asia Pacific is expected to grow at a high CAGR during the forecast period due to rising healthcare expenditure and increasing awareness about demineralized bone matrix products in the region.
Explore More Related Article On – Demineralized Bone Matrix Market
Get More Insights on- Demineralized Bone Matrix Market
